POSITION STATEMENT

Changing the name of diabetes insipidus: a position statement of The Working Group for Renaming Diabetes Insipidus

The Working Group for Renaming Diabetes Insipidus, Hiroshi Arima¹,², Timothy Cheetham³,⁴, Mirjam Christ-Crain⁵,⁶, Deborah Cooper⁷, Mark Gurnell⁸,⁹, Juliana B Drummond¹⁰,¹¹, Miles Levy¹²,¹³, Ann I McCormack¹⁴,¹⁵, Joseph Verbalis¹⁵,¹⁶, John Newell-Price¹⁶,¹⁷ and John A H Wass¹⁸,¹⁹

¹Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan
²Japan Endocrine Society
³Department of Paediatric Endocrinology, Newcastle University Faculty of Medical Sciences, Great North Children’s Hospital, Royal Victoria Infirmary, Newcastle upon Tyne, UK
⁴European Society for Pediatric Endocrinology
⁵Department of Endocrinology, Diabetes and Metabolism, University Hospital Basel, University of Basel, Switzerland
⁶European Society of Endocrinology
⁷Pituitary Foundation, Bristol, UK
⁸Wellcome-MRC Institute of Metabolic Science, University of Cambridge & Addenbrooke's Hospital, Cambridge Biomedical Campus, Cambridge, UK
⁹Faculdade de Medicina da UFMG, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
¹⁰Brazilian Society of Endocrinology and Metabolism
¹¹Endocrinology, University Hospitals of Leicester, Leicester, UK
¹²Society for Endocrinology
¹³Hormones and Cancer Group, Garvan Institute of Medical Research, Sydney, New South Wales, Australia
¹⁴Endocrine Society of Australia
¹⁵Endocrinology and Metabolism, Georgetown University Medical Center, Washington DC, District of Columbia, USA
¹⁶Endocrine Society
¹⁷Department of Oncology and Metabolism, The Medical School, University of Sheffield, Sheffield, UK
¹⁸Department of Endocrinology, Oxford Centre for Diabetes Endocrinology & Metabolism – Endocrinology, Oxford, UK
¹⁹Pituitary Society

Correspondence should be addressed to M Christ-Crain or J Verbalis: mirjam.christ-crain@usb.ch or verbalis@georgetown.edu

This article is CC BY and has been published in the following titles: Archives of Endocrinology and Metabolism, Clinical Endocrinology, Endocrine Connections, Endocrine Journal, European Journal of Endocrinology, Hormone Research in Pediatrics, Pituitary and The Journal of Clinical Endocrinology and Metabolism. The articles are identical except for minor stylistic and spelling differences in keeping with each journal’s style. A citation specific to one of the journals may be used when citing this article.

Abstract

‘What’s in a name? That which we call a rose/By any other name would smell as sweet’ (Juliet, from Romeo and Juliet by William Shakespeare). Shakespeare’s implication is that a name is nothing but a word, and it therefore represents a convention with no intrinsic meaning. While this may be relevant to romantic literature, disease names do have real meanings, and consequences, in medicine. Hence, there must be a very good rationale for changing the name of a disease that has a centuries-old historical context. A working group of representatives from national and international endocrinology, and pediatric endocrine societies now proposes changing the name of ‘diabetes insipidus’ to ‘arginine vasopressin deficiency (AVP-D)’ for central etiologies, and ‘arginine vasopressin resistance (AVP-R)’ for nephrogenic etiologies. This article provides both the historical context and the rationale for this proposed name change.

Key Words
- renaming
- diabetes insipidus
Reasons for changing a disease name

Understanding of disease processes is a dynamic field, with rapidly evolving concepts of pathophysiology based on emerging molecular and genetic data. Consequently, newer understanding of pathophysiology is one of the major reasons for renaming diseases. In endocrinology, appreciation of hyperprolactinemia as the common pathophysiology underlying many different clinical situations causing galactorrhea and amenorrhea led to the effective abandonment of many previous eponymous names for these conditions, such as Chiari–Frommel syndrome, Forbes–Albright syndrome and Ahumada–del Castillo syndrome (1). A second reason is based on historical discoveries that a previous eponymous name for a syndrome was inappropriately attributed to an individual who was not the first or even the most significant person involved in the description of the syndrome (2). A third reason is later appreciation of medically unethical behaviors of individuals with diseases eponymously named for them, as characterized by the renaming of Reiter’s syndrome to ‘reactive arthritis’ and Wegener’s granulomatosis to ‘granulomatosis with polyangiitis’, because of the association of the eponymous physicians with Nazi antihumanitarian crimes (3, 4). The first three of these reasons for changing disease names make a strong case for detaching eponyms from disease processes whenever possible (5). However, endocrinologists would be loathe to abandon the eponyms of Addison, Cushing, Hashimoto and others for their unique and seminal contributions to our understanding of endocrine disease processes. However, yet a fourth reason for renaming diseases is when traditional disease names lead to confusion between pathophysiologically different processes, leading to treatment errors and consequent adverse outcomes for patients. This last reason represents the major impetus to change the name of diabetes insipidus at this time.

Historical context

Before explaining the rationale for the name change, it is instructive to review the historical context for the name of diabetes insipidus. The polyuria and polydipsia of diabetes were first described by Demetrius of Apameia (1st–2nd century BC), who used the term ‘diabetes’, meaning ‘passing water like a siphon’ to describe the polyuria characteristic of this condition. Araetus of Cappadocia (81–138 AD) further defined the clinical characteristics of this disease (6). Although observations that the urine was sweet were alluded to in both Greek and Indian history, the first documented report of the sweet character of diabetic urine was published by the English physician Sir Thomas Willis in 1674 (The Diabetes or Pissing Evil). However, the differentiation between the saccharine urine of glucosuria and the non-saccharine urine of other forms of polyuria is attributed to the Scottish physician William Cullen, who appended the Latin word ‘mellitus’ (sweet) to the Greek term ‘diabetes’ to distinguish between these two types of polyuria (7). In 1794, Johann Peter Frank first introduced the term ‘diabetes insipidus’ to differentiate these patients from those with diabetes mellitus (7). These terms persisted as valid clinical descriptions without known pathophysiology until the vasopressor and antidiuretic actions of posterior pituitary extracts were discovered in the late 19th and early 20th centuries, including the use of posterior pituitary extracts to treat diabetes insipidus. In the mid-20th century, arginine vasopressin (AVP) was synthesized and identified as the antidiuretic hormone, and the distinct central and nephrogenic etiologies of diabetes insipidus were recognized and characterized (8). Despite new knowledge of the underlying pathophysiology of the different etiologies of diabetes insipidus by the late 20th century, no attempts were made to rename diabetes insipidus according to the known causes of the disorder, namely, deficiency of AVP or resistance to the receptor-mediated actions of AVP.

Rationale for changing the name of diabetes insipidus

There are multiple reasons for changing the name of diabetes insipidus at this time. First and foremost, although the terms ‘mellitus’ and ‘insipidus’ do differentiate between the clinical characteristics of these two very different causes of polyuria, and clearly are not eponyms, the use of the common term ‘diabetes’ in both has unfortunately led to confusion for both patients and their caretakers. This confusion with diabetes mellitus has been to the detriment of patients with diabetes insipidus when they are under the care of non-endocrine specialists. Some physicians and nurses do not appreciate the difference between these two very different disorders. In several patients with central diabetes insipidus, desmopressin treatment was withheld with serious adverse outcomes, including death (9). This has led to high-profile litigation cases and coroners’ inquests involving the police, with wide media coverage. Subsequent to these unfortunate but avoidable cases, national safety alerts, surveys among
endocrinologists, and a global taskforce consisting of a wide range of senior clinicians involved with the care of patients with diabetes insipidus, have led to a strong impetus to change the name of the condition. Secondly, patients with diabetes insipidus strongly support changing the name to eliminate ‘diabetes’. In a survey of >1000 patients with central diabetes insipidus recently published in The Lancet Diabetes & Endocrinology (10), 85% preferred the name to be changed, mainly because of experiences with insufficient understanding of the disease by health professionals who confused this disorder with diabetes mellitus. Eighty-seven percent of patients felt that this lack of knowledge and the resulting clinical confusion affected the management of their condition, for example, repeated blood sugar measurements or prescription of medication for diabetes mellitus during hospitalization. Finally, we believe the names of medical disorders should, ideally, reflect the underlying pathophysiology, which in the case of diabetes insipidus is now well known to be deficient secretion and/or end-organ effects of the hormone AVP. Hence, for all the above reasons, the working group proposes that the name diabetes insipidus should be changed to ‘arginine vasopressin deficiency (AVP-D)’ for central etiologies and ‘arginine vasopressin resistance (AVP-R)’ for nephrogenic etiologies, and this proposal has been endorsed by the following societies represented by the working group members: Endocrine Society, European Society of Endocrinology, Pituitary Society, Society for Endocrinology, European Society for Paediatric Endocrinology, Endocrine Society of Australia, Brazilian Endocrine Society, and Japan Endocrine Society, and is under review at several other societies.

We fully recognize that changing a name for a long-standing disease is never easy. However, just as the rheumatologists who proposed the name change of granulomatosis with polyangiitis (Wegener’s granulomatosis) (4), we hope our medical colleagues will recognize and accept the above rationale for making this change, not only in the interest of scientific accuracy, but more so for the benefit and safety of our mutual patients with diabetes insipidus, so that their disease and its treatment will no longer be confused with diabetes mellitus.

Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of this position statement.

Funding
This work did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

Acknowledgements
The Working Group for Renaming Diabetes Insipidus: Hiroshi Arima for the Japan Endocrine Society; Timothy Cheetham for the European Society for Paediatric Endocrinology; Mirjam Christ-Crain and Mark Gurnell for the European Society of Endocrinology; Deborah Cooper, patient representative; Juliana B Drummond for the Brazilian Society of Endocrinology and Metabolism; Miles Levy and Mark Gurnell for the Society for Endocrinology; Ann I McCormack for the Endocrine Society of Australia; Joseph Verbalis and John Newell-Price for the Endocrine Society; John A H Wass for the Pituitary Society.

References
1. Venturini PL, Capitiano GL, Bocardo E, Ferraro R, Rossato P & De Cecco L. The amenorrhoea-galactorrhoea syndrome: present diagnostic and therapeutic perspectives. Acta Europaea Fertililitatis 1975 6 331–338.
2. Matteson EL. Notes on the history of eponymic idiopathic vasculitis: the diseases of Henoch and Schonlein. Arthritis Care and Research 2000 13 237–245. (https://doi.org/10.1002/1529-0131(200008)13:4<237::aid-anr8>3.0.co;2-i)
3. Lu DW & Katz KA. Declining use of the eponym ‘Reiter’s syndrome’ in the medical literature, 1998–2003. Journal of the American Academy of Dermatology 2005 53 720–723. (https://doi.org/10.1016/j.jaad.2005.06.048)
4. Woywodt A, Haubitz M, Hailer H & Matteson EL. Wegener’s granulomatosis. Lancet 2006 367 1362–1366. (https://doi.org/10.1016/S0140-6736(06)68583-8)
5. Matteson EL. All medical eponyms should be abandoned. Presse Medico 2008 37 250–251. (https://doi.org/10.1016/j.pmed.2007.11.005)
6. Gemmill CL. The Greek concept of diabetes. Bulletin of the New York Academy of Medicine 1972 48 1033–1036. (available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1806843/)
7. Lindholm J. Diabetes insipidus: historical aspects. Pituitary 2004 7 33–38. (https://doi.org/10.1023/b:pitu.00000044633.52516.e1)
8. Robertson GL. Thirst and vasopressin function in normal and disordered states of water balance. Journal of Laboratory
9 Prentice M. Time for change: renaming diabetes insipidus to improve patient safety. *Clinical Endocrinology* 2018 88 625–626. (https://doi.org/10.1111/cen.13378)

10 Atila C, Loughrey PB, Garrahy A, Winzeler B, Refardt J, Gildroy P, Hamza M, Pal A, Verbalis JG, Thompson CJ, et al. Central diabetes insipidus from a patients' perspective: management, psychological co-morbidities, and re-naming of the condition. *Lancet: Diabetes and Metabolism* 2022 [epub]. (https://doi.org/10.1016/S2213-8587(22)00219-4)

Received in final form 30 August 2022
Accepted 30 August 2022